Therapy Areas: Oncology
NeoPhore names Matthew Baker PhD as CEO
17 March 2020 -

Oncology company NeoPhore Limited revealed on Monday the election of Matthew Baker PhD as its chief executive officer (CEO), with immediate effect.

Prior to the promotion, Dr Baker has served as the vice president of Immunology at NeoPhore and will succeed the outgoing Jeff Roix.

Previously, Dr Baker was employed as the chief scientific officer of Denceptor Therapeutics Ltd and Abzena plc , chief executive officer and cofounder of Antitope Ltd and vice president for Biologics Discovery at Biovation Ltd.

Currently, Dr Baker is the non-executive director at Oxgene Ltd.

Login
Username:

Password: